| Author | Motta, Edwiges | |
| Author | Camacho, Luiz Antonio B. | |
| Author | Cunha, Marcelo | |
| Author | Filippis, Ana Maria Bispo de | |
| Author | Lima, Sheila M. B. | |
| Author | Costa, Marcellus | |
| Author | Pedro, Luciana | |
| Author | Cardoso, Sandra W. | |
| Author | Cortes, Fernanda Heloise | |
| Author | Giacoia-Gripp, Carmem B. W. | |
| Author | Morata, Michelle | |
| Author | Nazer, Sandro | |
| Author | Moreira, Ronaldo Ismério | |
| Author | Souza, Marta Cristina de Oliveira | |
| Author | Mendes, Ygara S. | |
| Author | Azevedo, Adriana de Souza | |
| Author | Alvez, Nathalia dos Santos | |
| Author | Grinsztejn, Beatriz | |
| Author | Coelho, Lara E. | |
| Access date | 2024-03-05T12:21:05Z | |
| Available date | 2024-03-05T12:21:05Z | |
| Document date | 2023 | |
| Citation | MOTTA, Edwiges et al. Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV. AIDS, v. 37, n. 15, p. 2319-2329, Dec. 2023. | en_US |
| ISSN | 0269-9370 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/62908 | |
| Language | eng | en_US |
| Publisher | Wolters Kluwer Health | en_US |
| Rights | open access | |
| Title | Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV | en_US |
| Type | Article | |
| DOI | 10.1097/QAD.0000000000003696 | |
| Abstract | Objective: To evaluate immunogenicity and reactogenicity of yellow fever (YF) vaccine in people with HIV (PWH) compared to HIV-uninfected controls. Design: In this longitudinal interventional trial (NCT03132311), PWH with CD4+ cell count 200 cells/ml and controls, aged 18–59, without a previous history of YF vaccination received a single standard dose of YF vaccine (17DD) and were followed at Days 5, 30 and Year 1. Methods: YF-neutralization titers were measured at Days 0, 30 and Year 1 and geometric mean titers (GMT) were calculated. Adverse events (AE) and YF virus detection were measured at Days 5 and 30. Linear regression evaluated factors associated with YF-neutralization titers. Results: Two hundred and eighteen PWH and 82 controls were included. At baseline, all PWH were using antiretroviral therapy; 92.6% had undetectable HIV viral load (VL) and median CD4+ cell count was 630 cells/ml [interquartile range (IQR) 463–888]. YF vaccine was safe and there were no serious AEs. At Day 30, seroconversion was observed in 98.6% of PWH [95% confidence interval (CI): 95.6–99.6] and in 100% of controls (95% CI: 93.9–100); at Year 1, 94.0% of PWH (95% CI: 89.6–96.7) and 98.4% of controls (95% CI 90.3–99.9) were seropositive. PWH had lower GMTs than controls at Day 30 and Year 1. Baseline VL >1000 copies/ml, low CD4+ cell count and low CD4+/CD8+ ratio were associated with lower YF-neutralization titers. Conclusions: YF vaccine is safe in PWH with CD4+ cell count 200 cells/ml. YF vaccine immunogenicity is impaired in PWH, particularly among those with high VL, low CD4+ cell count and low CD4+/CD8+ ratio at vaccination and YF-neutralization titers decays over time. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Departamento de Desenvolvimento Experimental e pré-Clínico. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Laboratório de Tecnologia Virológica. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Laboratório de Tecnologia Virológica. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Laboratório de Análise Imunomolecular. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Laboratório de Análise Imunomolecular. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil. | |
| Subject | HIV/AIDS | en_US |
| Subject | Immunogenicity | en_US |
| Subject | Neutralizing Antibodies | en_US |
| Subject | People with HIV | en_US |
| Subject | Safety | en_US |
| Subject | Yellow Fever Vaccine | en_US |
| e-ISSN | 1473-5571 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
